

## **Environmental and Social Data Sheet**

### **Overview**

Project Name:	COVID-19 VACCINE VOLUME ALLOCATION II
Project Number:	2021-0040
Country:	Regional – Africa, Regional – Asia, Regional - Latin America
Project Description:	Project to support the supply of COVID-19 vaccines for low and middle income countries via the COVAX AMC framework co-led by Gavi.
EIA required:	no
Project included in Carbon Footprint Exercise :	no

### **Environmental and Social Assessment**

The project contributes to the COVAX initiative, a funding mechanism for the procurement and distribution of successful SARS-CoV-2 vaccines. The Bank's facility supports vaccine distribution in the countries of Sub-Saharan Africa and the European Neighbourhood.

#### **Environmental Assessment**

Due to the project's characteristics, the project does not fall under Annex I or Annex II of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

#### **Social Assessment, where applicable**

The project, if successful, is expected to lead to important social benefits stemming from its focus on ensuring fair and equitable access to vaccines successfully developed against the SARS CoV-2 virus. SARS-CoV-2 and the resulting disease COVID 19, are areas of high unmet medical need that have severely congested public health systems and services worldwide and have effectively paralysed the global economy. The need for global equitable access to a SARS-CoV-2 vaccine is significant.

The project is expected to have a significant impact on gender equality. The project is deployed under the guidance of an allocation model, developed by WHO. The allocation model is shaped by context specific social vulnerability analysis (which is highly likely to draw on sex-disaggregated data and include a gender analysis) in order to identify who is most vulnerable and should be prioritised when rolling out vaccinations. The allocation model prioritises those who are systematically disadvantaged with respect to social standing and economic and political power.

Luxembourg, 05 May 2021

### **Other Environmental and Social Aspects**

The project supports the equitable and fair procurement and distribution of a SARS-CoV-2 vaccine and it therefore contributes to the EU coordinated response to the COVID 19 crisis. Successful vaccines to combat the disease pandemic will reinforce public health sectors and mitigate the socio-economic impact of the disease globally.

### **Conclusions and Recommendations**

The project concerns investments in vaccines, activities for which do not fall under Annex I or Annex II of the EIA Directive.

The activities undertaken in the project aim to result in new and improved vaccine access with a positive impact on healthcare. Therefore, if the project is successful, it is expected to have a positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects.